- Home
- DMA vs NRXP Comparison
DMA vs NRXP Comparison
Compare DMA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | NRXP |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 63.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DMA | NRXP |
|---|---|---|
| Price | $9.07 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 34.6K | ★ 461.4K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $1.15 |
| 52 Week High | $8.00 | $6.01 |
Technical Indicators
Market Signals| Indicator | DMA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 74.49 | 41.42 |
| Support Level | $8.63 | $2.22 |
| Resistance Level | $8.79 | $2.39 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 92.62 | 40.74 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.